Tag: Data

Castle Biosciences Presents Data at the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting


Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced that its data were featured in two oral presentations during the 2020 American Society for Dermatologic Surgery (ASDS) Virtual Annual Meeting, Oct. 9-11, 2020.


DecisionDx®-Melanoma: Skin Cancer and Reconstruction Session; Friday, October 9, 2020


“Cutaneous Melanoma Prognostic Model Combining 31-gene Expression Profile and Sentinel Lymph Node Biopsy” was presented by Aaron Farberg, M.D., Baylor University Medical Center, Dallas, Texas.


DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors.


“As most sentinel lymph node biopsies are negative, there is a need to identify which melanoma patients can forgo sentinel lymph node biopsy (SNLB),” said Dr. Farberg. “Based on the cohort described in a recent meta-analysis by Greenhaw and colleagues, we modeled the use of Castle’s DecisionDx-Melanoma test to determine whether it might alter the predictive value of SLNB alone in high-risk patients, and whether the test might identify patients who would not benefit from SLNB. In fact, we found that use of the test stratifies risk in the cohort studied, which can help focus the resources needed for SLNB on patients with genuinely higher risk, thereby reducing surgical risks for patients who can avoid SLNB.”


Study methods and findings:


  • The study objective was to model the use of DecisionDx-Melanoma to triage cutaneous melanoma patients for SLNB, to evaluate the outcomes of low-risk patients who can forgo SLNB and to evaluate the combined accuracy of DecisionDx-Melanoma and SLNB in high-risk patients.

  • The model was based on use of DecisionDx-Melanoma to triage the patients from the recently published systematic review and meta-analysis (Greenhaw et al. JAAD, Sept., 2020), assuming that:

    • Patients with a Class 1A result who were 55 years of age or older with T1-T2 melanoma would not undergo SLNB;

    • The negative predictive value of DecisionDx-Melanoma for recurrence-free survival, distant metastasis free survival and ultimately melanoma specific survival would be high for patients who would not have undergone SLNB due to DecisionDx-Melanoma triage; and

    • The remaining patients would undergo SLNB.

  • Result showed that:

    • 69% of all patients could forgo an SLNB due to a DecisionDx-Melanoma Class 1A test result, and the negative predictive value for 5-year melanoma specific survival was 98%.

    • For the remaining 31% of patients who would undergo an SLNB:

      • Sensitivity for melanoma specific death was 87% for DecisionDx-Melanoma compared with 73% for SLNB. Combining DecisionDx-Melanoma with SLNB improved sensitivity to 96%.

      • Negative predictive value for melanoma specific death was 95% for DecisionDx-Melanoma, compared with 94% for SLNB. Combining DecisionDx-Melanoma with SLNB improved negative predictive value to 98%.

  • The study concluded that use of DecisionDx-Melanoma to triage patients with
Continue reading

Tricida Announces Twelve Data Presentations on Veverimer and Metabolic Acidosis to be Given at the Virtual American Society of Nephrology Kidney Week 2020

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer (TRC101), a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD), announced today that it has authored or sponsored 12 presentations at the upcoming American Society of Nephrology (ASN) Kidney Week 2020 being held virtually October 22-25, 2020. Data to be presented at multiple sessions at the meeting will expand the breadth of information about the implications of metabolic acidosis and CKD. All Tricida presentations will be available on Thursday, October 22, 2020 at 10:00am ET. Session and presentation titles are listed below:

Session Title: CKD Risk Factors: Diet, Environment, Lifestyle

Title:

Relationship Between Metabolic Acidosis and Chronic Kidney Disease Progression is Evident Across United States Racial and Ethnic Groups

Author:

N. Tangri et al.

ePoster #:

PO0468

 

 

Title:

Metabolic Acidosis is Associated with Chronic Kidney Disease Progression: A Longitudinal Analysis of >100,000 United States Community-Based Patients

Author:

V. Mathur et al.

ePoster #:

PO0469

 

 

Title:

Metabolic Acidosis and Progression to Renal Replacement Therapy (Encore Presentation)

Author:

V. Mathur et al.

ePoster #:

PO0467

Session Title: Advances in Geriatric Nephrology

Title:

Effects of Veverimer on Serum Bicarbonate and Physical Function in Elderly Patients with Metabolic Acidosis in Chronic Kidney Disease

Author:

D. Wesson et al.

ePoster #:

PO1685

 

 

Title:

Correlation Between Patient-Reported Physical Limitation and Objective Physical Performance on the Repeated Chair Stand Test Among Patients with Non-Dialysis Dependent Chronic Kidney Disease and Metabolic Acidosis

Author:

V. Mathur et al.

ePoster #:

PO1687

Session Title: CVD, BP, and Kidney Diseases: Exploring the Link

Title:

No Adverse Effects of Veverimer on Volume Status or Blood Pressure in Patients with Chronic Kidney Disease and Metabolic Acidosis

Author:

D. Wesson et al.

ePoster #:

PO2116

Session Title: Women’s Health and Kidney Diseases

Title:

Effects of Veverimer on Serum Bicarbonate and Physical Function in Women with Chronic Kidney Disease: A Subgroup Analysis from a Randomized Controlled Trial

Author:

V. Mathur et al.

Session:

Women’s Health and Kidney Diseases

ePoster #:

PO2612

Session Title: Diabetic Kidney Disease: Clinical – 2

Title:

Effects of Veverimer on Serum Bicarbonate and Physical Function in Patients with Diabetes and Chronic Kidney Disease: Subgroup Analysis from a Randomized Trial (Encore presentation)

Author:

D. Wesson et al.

ePoster #:

PO1033

Session Title: Fluid, Electrolyte, and Acid-Base Disorders: Clinical – 2

Title:

Metabolic Acidosis is a Predictive Factor for All-Cause Mortality in Patients with Chronic Kidney Disease (Encore presentation)

Author:

N. Tangri et al.

ePoster #:

PO1483

Session Title: Pharmacology (PharmacoKinetics, -Dynamics, -Genomics)

Title:

Action of Veverimer on Gastrointestinal Acid Binding is Not Affected by Omeprazole

Author:

D. Parsell et al.

ePoster #:

PO2374

 

 

Title:

Evaluation of Veverimer Drug Interaction Potential (Encore presentation)

Author:

J. Shao et al.

ePoster #:

PO2373

Session Title: Informational Posters

Title:

Understanding the Long-Term Impact of Metabolic Acidosis in Chronic Kidney Disease: Design of the ULTIMA-CKD Patient Registry

Author:

V. Mathur et al.

ePoster #:

INFO16

Continue reading

Dicerna to Present Nedosiran Data at American Society of Nephrology (ASN) Kidney Week 2020

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that clinical data on nedosiran, an investigational candidate for the treatment of primary hyperoxaluria (PH), will be presented during the American Society of Nephrology (ASN) Kidney Week taking place Oct. 22-25, 2020. In addition, a commercial claims analysis of clinical and economic burden associated with PH will also be presented.

The following poster presentations will be available during the “Genetic Diseases of the Kidneys: Non-Cystic – 1” session taking place on Thursday, Oct. 22, 2020 at 10:00 a.m. ET:

  • Title: PHYOX™3: A Long-Term, Open-Label Extension Trial of Nedosiran in Patients With Primary Hyperoxaluria Type 1, 2 or 3
    Poster #: PO1625

About Primary Hyperoxaluria

Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys. There are three known types of PH (PH1, PH2 and PH3), each resulting from a mutation in one of three different genes. These genetic mutations cause enzyme deficiencies that result in the overproduction of a substrate called oxalate. Abnormal production and accumulation of oxalate leads to recurrent kidney stones, nephrocalcinosis and chronic kidney disease that may progress to end-stage renal disease, requiring intensive dialysis. Compromised renal function eventually results in the accumulation of oxalate in organs ranging from skin, bones, eyes and heart. In the most severe cases, symptoms start in the first year of life. A combined liver-kidney transplantation may be undertaken to resolve PH1 or PH2, but it is an invasive solution with limited availability and high morbidity that requires lifelong immune suppression to prevent organ rejection. There are currently no approved medications for the treatment of PH. Patients are limited to using hyperhydration and medication to attempt to increase solubility of oxalate in urine. Despite these interventions, oxalate may continue to accumulate in the kidneys and other organs, causing damage.

About Nedosiran

Nedosiran is the only RNAi drug candidate in development for primary hyperoxaluria (PH) types 1, 2 and 3 and is Dicerna’s most advanced product candidate utilizing the proprietary GalXC™ RNAi technology platform. Nedosiran is designed to reduce the levels of hepatic lactate dehydrogenase (LDH) enzyme – an enzyme that catalyzes the final step in a common pathway resulting in oxalate overproduction in patients with PH1, PH2 and PH3. Dicerna is evaluating the safety and efficacy of nedosiran in patients with all known forms of PH as part of its PHYOX™ clinical development program.

About Dicerna Pharmaceuticals, Inc.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) is a biopharmaceutical company focused on discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. Using our proprietary RNAi technology platform called GalXC™, Dicerna is committed to developing RNAi-based therapies with the potential to treat both rare and more prevalent diseases. By silencing disease-causing genes, Dicerna’s GalXC platform has the potential to address conditions that are difficult to treat with other modalities.

Continue reading

Trudeau says ‘we’re at a tipping point’ amid latest modelling data, new government benefits

Canada’s top health officials provided an update on the nation’s latest modelling data, which projects how COVID-19 will continue to spread throughout the country. 

Canada could see up to 5,000 cases a day by late October to early November if we maintain our current levels of contacts, according to just-released modelling data.

“We’re at a tipping point in this pandemic,” Prime Minister Justin Trudeau said, noting the country reported its most-ever daily cases on Thursday with 2,437 new infections.

Canada could see up to 5,000 new cases a day by late October if we don’t limit contacts

The latest modelling data by Public Health Agency of Canada shows that by Oct. 17, there could be 188,150-197,830 cases in the country, while the death toll is expected to increase to 9,690-9,800.

On Thursday — after Canada recorded its most-ever cases in a day with 2,437 — there were 175,559 total diagnoses and 9,557 deaths. Federal data projects that the country will see at least 133 additional fatalities and 12,591 more cases by Oct. 17.

“The acceleration of epidemic growth is concerning,” Chief Public Health Officer of Canada Dr. Theresa Tam said. “The actions of individual Canadians are needed now to reverse this trend.”

Modelling data also shows that Canada may see up to 5,000 cases a day by late October to early November if we maintain our current levels of contacts. If Canadians decrease them by 25-35 per cent, we could see fewer than 3,000 cases a day by November, according to the data.

Credit: Public Health Agency of Canada
Credit: Public Health Agency of Canada

Tam said that the individual actions of people in some areas of the country have not been enough to decrease transmission. Therefore, such as in areas like Quebec and Ontario, additional measures have been in place, including strategic business closures in “order to put the brakes on the epidemic.”

Tam said that by acting fast and imposing restrictions, we have the best chance of limiting the spread and avoiding the public health system being overburdened.

“We are at an important juncture in the pandemic where we would very much like to see the voluntary actions of Canadians across the country be sufficient to bend the curve downward,” Tam added.

Tam, along with Trudeau and several other ministers, stressed the importance of limiting contacts this Thanksgiving weekend.

Credit: Public Health Agency of Canada
Credit: Public Health Agency of Canada

Along with the recent projections, the data showed how that across Canada trends vary, with the highest increase in cases occurring in Quebec, Ontario and Alberta. In contrast, there hasn’t been a significant resurgence in cases in the Atlantic bubble, which consists of Prince Edward Island, Nova Scotia, New Brunswick and Newfoundland and Labrador. There also hasn’t been any community transmission in the territories.

Credit: Public Health Agency of Canada
Credit: Public Health Agency of Canada

Canada’s time-varying effective reproduction number (Rt), represents how many people are being infected by each new case. When it’s less than 1, it means that the “epidemic will die out.” However, Canada’s RT has been greater than

Continue reading

Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting

IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ — Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020.

The scheduled times (noted in local Eastern Standard Time) of the presentations, titles and authors are as follows.

Oral presentations include:

  • Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers: A Pooled Analysis
  • Authors: Joely Kaufman, Patricia Ogilvie, Kenneth Beer, Alexander Rivkin, Sarah Baradaran, Andrew Schumacher
  • Presenter: Joely Kaufman, MD
  • Saturday, October 10th, 11:27 a.m.
  • Treatment of Upper Facial Lines With OnabotulinumtoxinA Results in Long-Lasting Efficacy and Patient Satisfaction
    • Authors: Joel L. Cohen, Koenraad De Boulle, Steven Fagien, Jean Carruthers, Sue Ellen Cox, Patricia Ogilvie, Julie Garcia, Sara Sangha
    • Presenter: Joel L. Cohen, MD
    • Sunday, October 11th, 10:27 a.m.

    The following posters will be on display and available for the entire length of the ASDS Virtual Annual Meeting.

    • Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines
    • Authors: Sue Ellen Cox, John H. Joseph, Steven Fagien, Dee Anna Glaser, Suzanne Bruce, Edward Lain, Steven Yoelin, Melanie Palm, Corey S. Maas, Xiaofang Lei, John Maltman, Sara Sangha, Mitchell Brin
  • Global Patient Perspectives on Skin Quality in Facial Aesthetics
    • Authors: Noëlle Sherber, Annie Chiu, Arisa Ortiz, Shannon Humphrey, Jeanine Downie, Sabrina Fabi

    Complete abstracts, details on presentation times and changes to presentation dates can be found on the ASDS website. The above listed dates are subject to change. Please check www.asds.net for the latest information.

    IMPORTANT SAFETY INFORMATION & APPROVED USES
    BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

    • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
    • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

    BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
    There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow’s feet lines, and/or forehead lines.
    BOTOX® Cosmetic may cause loss of strength or general

    Continue reading

    Allergan Aesthetics To Present Data From 4 Abstracts At The 2020 American Society For Dermatologic Surgery Virtual Meeting | Nachricht

    IRVINE, Calif., Oct. 9, 2020 /PRNewswire/ –Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced today that it will present 4 abstracts at the annual American Society for Dermatologic Surgery (ASDS) virtual meeting from October 9-11, 2020.

    The scheduled times (noted in local Eastern Standard Time) of the presentations, titles and authors are as follows.

    Oral presentations include:

    • Patient Satisfaction Following Chin Augmentation With Hyaluronic Acid Fillers: A Pooled Analysis
    • Authors: Joely Kaufman, Patricia Ogilvie, Kenneth Beer, Alexander Rivkin, Sarah Baradaran, Andrew Schumacher
    • Presenter: Joely Kaufman, MD
    • Saturday, October 10th, 11:27 a.m.
  • Treatment of Upper Facial Lines With OnabotulinumtoxinA Results in Long-Lasting Efficacy and Patient Satisfaction
    • Authors: Joel L. Cohen, Koenraad De Boulle, Steven Fagien, Jean Carruthers, Sue Ellen Cox, Patricia Ogilvie, Julie Garcia, Sara Sangha
    • Presenter: Joel L. Cohen, MD
    • Sunday, October 11th, 10:27 a.m.

    The following posters will be on display and available for the entire length of the ASDS Virtual Annual Meeting.

    • Safety, Pharmacodynamic Response, and Treatment Satisfaction With OnabotulinumtoxinA 40 U, 60 U, and 80 U in Subjects With Moderate to Severe Dynamic Glabellar Lines
    • Authors: Sue Ellen Cox, John H. Joseph, Steven Fagien, Dee Anna Glaser, Suzanne Bruce, Edward Lain, Steven Yoelin, Melanie Palm, Corey S. Maas, Xiaofang Lei, John Maltman, Sara Sangha, Mitchell Brin
  • Global Patient Perspectives on Skin Quality in Facial Aesthetics
    • Authors: Noëlle Sherber, Annie Chiu, Arisa Ortiz, Shannon Humphrey, Jeanine Downie, Sabrina Fabi

    Complete abstracts, details on presentation times and changes to presentation dates can be found on the ASDS website. The above listed dates are subject to change. Please check www.asds.net for the latest information.

    IMPORTANT SAFETY INFORMATION & APPROVED USES
    BOTOX® Cosmetic may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of BOTOX® Cosmetic:

    • Problems swallowing, speaking, or breathing, due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months.
    • Spread of toxin effects. The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing.

    BOTOX® Cosmetic dosing units are not the same as, or comparable to, any other botulinum toxin product.
    There has not been a confirmed serious case of spread of toxin effect when BOTOX® Cosmetic has been used at the recommended dose to treat frown lines, crow’s feet lines, and/or forehead lines.
    BOTOX® Cosmetic may cause loss of strength or general muscle weakness,

    Continue reading

    Endo Aesthetics Data to be Featured in Five Presentations at the American Society for Dermatologic Surgery’s Annual Meeting (ASDS)

    DUBLIN, Oct. 9, 2020 /PRNewswire/ — Endo International plc (NASDAQ:ENDP) today announced that data relevant to the use of Endo Aesthetics’ Qwo™ (collagenase clostridium histolyticum-aaes) for the treatment of moderate to severe cellulite in the buttocks of adult women will be featured during the American Society for Dermatologic Surgery’s Annual Meeting (ASDS). These data will be highlighted in three posters and two oral presentations during the virtual meeting taking place October 9 – 11, 2020.

    Oral Presentations

    On Friday, October 9th a presentation titled “Results From a 1000+ Subject Survey Assessing Satisfaction With a Hypothetical 1-Point Improvement on the Validated Patient-Reported Photonumeric Cellulite Severity Scale (PR-PCSS) Analysis,” will be given by Sabrina Fabi, M.D., a board-certified dermatologist in California. Dr. Fabi will share results from a study designed to determine if a 1-point improvement in PR-PCSS score is a clinically meaningful outcome and will highlight the importance of patient education during consultations.

    On Sunday, October 11th, Melanie Palm, M.D., will present “Real-World Effectiveness and Safety of Collagenase Clostridium Histolyticum-aaes Injections for the Treatment of Thigh Cellulite in Women: An Interim Analysis”. During this presentation, Dr. Palm, a board-certified dermatologist and cosmetic surgeon in California, will outline the 90-day findings from ongoing phase 3b REAL™ and PIXELS™ studies assessing not only investigator-perceived and patient-reported results at 90-days, but also the quantitative corroboration of these findings, with 3D-image scans.

    Poster Presentations

    All poster presentations will be available for ASDS attendees throughout the Congress.

    • Title: Long-Term Durability of Collagenase Clostridium Histolyticum-aaes Treatment Effectiveness for Cellulite in Women
    • Authors: Joely Janette Kaufman, M.D., Vernon Leroy Young, M.D., Matthew Zook, M.D., Saji Vijayan, MBBS, D.Diab., Michael McLane PhD., Xiang Q Ph.D., Chajko KA, Lawrence Bass, M.D.
       
  • Title: Patient Retention Strategies for Long-Term Extension Aesthetic Studies: Collagenase Clostridium Histolyticum-aaes (QWO™) Phase 3 Clinical Study Experience
    • Authors: Joely Janette Kaufman, M.D., James Clark M.D., Kappa Peddy, M.D., Alex Cazzaniga Ph.D., Davina Cupo, Robert Yon, Rosalie Filling
       
  • Title: A Survey of Dermatology Healthcare Professional Knowledge, Perception, and Experience Regarding Cellulite and Its Treatment
    • Authors: Jill Edgecombe, Daniel Connolly, Sherry Chen, Stephanie Wenstrup

    “We are pleased with the breadth and depth of the data that will be presented at the ASDS meeting,” said Matthew Davis, M.D., R.Ph., Senior Vice President and Chief Medical Officer of Endo. “Endo Aesthetics is committed to offering aesthetic healthcare providers data not only on the safety and efficacy of QWO, but also on the real world implications of this treatment, including patient retention and perceptions, as we prepare for the product’s launch in spring 2021.”

    INDICATION
    QWO is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

    IMPORTANT SAFETY INFORMATION FOR QWO CONTRAINDICATIONS
    QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites.

    WARNINGS AND PRECAUTIONS
    Hypersensitivity Reactions
    Serious hypersensitivity

    Continue reading

    Google is sharing user data tied to search keywords with law enforcement

    Google is still drawing criticism for the data it hands over to police. Detroit News reporter Robert Snell has reviewed court documents (via CNET) showing that Google handed over IP addresses for users who searched for a specific address shortly before someone set fire to the car of a witness in the racketeering case against accused sex offender R. Kelly. The search keyword warrant led to the arrest of Michael Williams, an associate of R. Kelly’s, on charges of both arson and witness tampering.

    Agents linked IP addresses to Williams’ phone number and followed up with a warrant for details of Williams’ Google account, finding that he also looked up phrases such as “witness intimidation” and “countries that don’t have extradition with the United States.” The investigators also obtained a search warrant to obtain location info from Verizon (Engadget’s parent company) showing that Williams’ phone had traveled from his town of Valdosta, Georgia to Kissimmee, Florida, where the witness lives.

    The filing had been submitted in July, but wasn’t made public until October 6th.

    Williams’ lawyer, Todd Spodek, intends to challenge the warrant for allegedly violating his client’s rights. Search warrants are normally targeted at a narrow group of likely suspects — this was aimed at anyone looking for certain terms. It could be “misconstrued or used improperly,” Spodek said.

    Experts are concerned that “reverse” warrants, including geofence warrants that target everyone in a given area, violate Fourth Amendment rights protecting against overly broad searches. A federal judge in Illinois has already ruled that the approach violates the Fourth Amendment, while New York politicians have proposed a bill banning the practice.

    We’ve asked Google for comment, although it declined to tell CNET how many keyword-related warrants it received since 2017, when Minnesota police asked for user data linked to searches in a fraud case. However many it has received, this puts further scrutiny on both police data gathering methods and the willingness of tech companies to comply. If there was a constitutional violation, Google might not have needed to honor the request in the first place.

    Source Article

    Continue reading

    UK Government’s Department For Education Broke GDPR Data Protection Laws

    The UK’s Department for Eduction (DfE) breaches GDPR in the way it handles pupil data, the Information Commissioner’s Office (ICO) has found.

    The ICO first began probing the DfE last year after it became the subject of numerous complaints. Human rights groups Liberty and DefendDigitalMe raised complaints about the department for failing to allow parents to see their child’s record in the National Pupil Data, its refusal to correct inaccurate date, and for “secretly” sharing information belonging to minors with the UK Home Office.

    At the time, the ICO said: “DFE is failing to comply fully with its data protection obligations, primarily in the areas of transparency and accountability, where there are far-reaching issues, impacting a huge number of individuals in a variety of ways.”

    The ICO released the findings of its months-long audit this week and has concluded that there are widespread data protection failings at the DfE. Of its 139 recommendations for improvement, 60% are classed as urgent or high priority.

    It found, for example, that the DfE is not providing “sufficient privacy information to data subjects”, that no data protection impact assessments (DPIAs) are being carried out at the correct and early stages of cases, and that no experts are involved in the creation of data storage or retention record system.

    The ICO also found that there is a lack of awareness among staff of data protection, “potentially upping the risk of data breaches”.

    “There is no formal proactive oversight of any function of information governance, including data protection, records management, risk management, data sharing and information security within the DfE, which along with a lack of formal documentation, means the DfE cannot demonstrate accountability to the GDPR,” the ICO’s report noted.

    “Limited reporting lines, monitoring activity and reporting means there is no central oversight of data processing activities. As a result, there are no controls in place to provide assurance that all personal data processing activities are carried out in line with legislative requirements.”

    In a statement, the DfE said it treats the handling of personal data “extremely seriously” and “thanks the ICO for its report which will help us further improve in this area.”

    “Since the ICO completed its audit, we’ve taken a number of steps to address the findings and recommendations, including a review of all processes for the use of personal data and significantly increasing the number of staff dedicated to the effective management of it,” a DfE spokesperson said.

    Source Article

    Continue reading

    ECJ limits government spying on citizens’ mobile and internet data

    David Goddard | Getty Images News | Getty Images

    LONDON — The top court in the European Union has delivered another blow to governments seeking to keep tabs on citizens through controversial spying techniques. 

    The European Court of Justice (ECJ), the EU’s highest legal authority, ruled Tuesday that member states cannot collect mass mobile and internet data on citizens.

    Forcing internet and phone operators to carry out the “general and indiscriminate transmission or retention of traffic data and location data” is against EU law, the court explained in its ruling.

    “However, in situations where a member state is facing a serious threat to national security that proves to be genuine and present or foreseeable, that member state may derogate from the obligation to ensure the confidentiality of data relating to electronic communications,” it continues.

    Even in these emergency scenarios, there are rules that must be adhered to.

    “Such an interference with fundamental rights must be accompanied by effective safeguards and be reviewed by a court or by an independent administrative authority,” the court said.

    The ruling, which has been eagerly anticipated by civil rights campaigners, is in response to several cases brought about by Privacy International and La Quadrature du Net.

    The campaign groups argued that surveillance practices in the U.K., France and Belgium go too far and violate fundamental human rights. The groups specifically took issue with the U.K.’s Investigatory Powers Act, a 2015 French decree related to specialized intelligence services, and a Belgian law on collection and retention of communications data that was introduced in 2016.

    “Today’s judgment reinforces the rule of law in the EU,” said Caroline Wilson Palow, legal director of Privacy International, in a statement. “In these turbulent times, it serves as a reminder that no government should be above the law. Democratic societies must place limits and controls on the surveillance powers of our police and intelligence agencies.”

    Palow added: “While the Police and intelligence agencies play a very important role in keeping us safe, they must do so in line with certain safeguards to prevent abuses of their very considerable power. They should focus on providing us with effective, targeted surveillance systems that protect both our security and our fundamental rights.”

    Opinion from EU court advisor

    The ruling comes after an advisor to the ECJ argued that the surveillance practices in the U.K, France and Belgium breached EU laws.

    Advocate General Manuel Campos Sanchez-Bordona said in January that EU law prohibits governments from forcing private companies to engage in bulk indiscriminate surveillance.

    He said it applies to all situations where governments force telecommunications companies to participate in mass surveillance programs.

    The ECJ ruling is the latest in a string of cases trying to limit the powers of governments to keep tabs on citizens.

    In July, the ECJ ruled that U.S. national security laws don’t protect EU citizens’ privacy.

    The court restricted how U.S. firms could send European user data to the U.S. after concluding EU citizens had no effective way to challenge American

    Continue reading